Role of P57KIP2 Immunohistochemical Expression in Histological Diagnosis of Hydatidiform Moles

  • Triratanachat, Surang (Division of Gynecologic Pathology and Cytology, Chulalongkorn University) ;
  • Nakaporntham, Pattawan (Placenta Related Disease Research Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University) ;
  • Tantbirojn, Patou (Placenta Related Disease Research Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University) ;
  • Shuangshoti, Shanop (Department of Pathology, Faculty of Medicine, Chulalongkorn University) ;
  • Lertkhachonsuk, Ruangsak (Placenta Related Disease Research Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University)
  • Published : 2016.06.01


Purpose: To determine the significance of P57KIP2 immunohistochemistry expression in the histopathological diagnosis of hydatidiform mole. Materials and Methods: Hydatidiform mole patients at King Chulalongkorn Memorial Hospital between January 1999 and December 2011 were recruited. Two gynecologic pathologists reviewed histopathologic slides to confirm diagnosis. Formalin-fixed, paraffin-embedded tissue sections were stained using a bstandard immunostaining system with monoclonal antibodies against P57KIP2 protein. Correlations among pathological features, immunohistochemical expression and clinical data were analyzed. Results: One hundred and twenty-seven hydatidiform mole patients were enrolled. After consensus review, 97 cases were diagnosed as complet (CHM) and 30 cases as partial (PHM). Discordance between the first and final H&E diagnoses was found in 19 cases (14.9%, k= 0.578). Significant pathological features to classify the type of hydatidiform mole are central cisterns, trophoblastic proliferation, trophoblastic atypia, two populations of villi, fetal vessels and scalloped borders. After performing immunohistochemistry for P57KIP2, 107 cases were P57KIP2 negative and 20 cases positive. Discordant diagnoses between final H&E diagnosis and P57KIP2 immunohistochemistry was identified in 12 cases (9.4%). Sensitivity of final H&E diagnosis for CHM was 89.7%; specificity was 95.0%. PHM sensitivity and specificity of final H&E diagnosis was 95.0% and 89.7%, respectively. Conclusions: Histopathological diagnosis alone has certain limitations in accurately defining types of hydatidiform mole; P57KIP2 immunohistochemistry is practical and can be a useful adjunct to histopathology to distinguish CHM from non-CHM.



  1. Crisp H, Burton JL, Stewart R, et al (2003). Refining the diagnosis of hydatidiform mole: image ploidy analysis and p57KIP2 immunohistochemistry. Histopathol, 43, 363-73.
  2. Fukunaga M, Katabuchi H, Nagasaka T, et al (2005). Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. Am J Surg Pathol, 29, 942-7.
  3. Garcia-Barriola V, de Gomez MN, Dickson-Gonzalez S, et al (2008). Utility of p57 protein(KIP2) in molar disease to determine its androgenetic origin. J Reprod Med, 53, 476-80.
  4. Genest DR, Dorfman DM, Castrillon DH (2002). Ploidy and imprinting in hydatidiform moles. Complementary use of flow cytometry and immunohistochemistry of the imprinted gene product p57KIP2 to assist molar classification. J Reprod Med, 47, 342-6.
  5. Hancock BW, Nazir K, Everard JE (2006). Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med, 51, 764-6.
  6. Hoffner L, Dunn J, Esposito N, et al (2008). P57KIP2 immunostaining and molecular cytogenetics: combined approach aids in diagnosis of morphologically challenging cases with molar phenotype and in detecting androgenetic cell lines in mosaic/chimeric conceptions. Hum Pathol, 39, 63-72.
  7. Hoffner L, Parks WT, Swerdlow SH, et al (2010). Simultaneous detection of imprinted gene expression (p57(KIP2)) and molecular cytogenetics (FICTION) in the evaluation of molar pregnancies. J Reprod Med, 55, 219-28.
  8. Howat AJ, Beck S, Fox H, et al (1993). Can histopathologists reliably diagnose molar pregnancy? J Clin Pathol, 46, 599-602.
  9. Ishikawa N, Harada Y, Tokuyasu Y, et al (2009). Re-evaluation of the histological criteria for complete hydatidiform mole: Comparison with the immunohistochemical diagnosis using p57KIP2 and CD34. Biomed Res, 30, 141-7.
  10. Javey H, Borazjani G, Behmard S, et al (1979). Discrepancies in the histological diagnosis of hydatidiform mole. Br J Obstet Gynaecol, 86, 480-3.
  11. Jeffers MD, O’Dwyer P, Curran B, et al (1993). Partial hydatidiform mole: a common but underdiagnosed condition. A 3-year retrospective clinicopathological and DNA flow cytometric analysis. Int J Gynecol Pathol, 12, 315-23.
  12. Jun SY, Ro JY, Kim KR (2003). p57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathol, 43, 17-25.
  13. Kim SJ, Lee C, Kwon SY, et al (2004). Studying changes in the incidence, diagnosis and management of GTD: the South Korean model. J Reprod Med, 49, 643-54.
  14. Lertkhachonsuk A, Israngura N, Tangtrakul S, et al (2012a). Complete hydatidiform mole change in clinical profile over three decades. J Reproductive Med, 57, 470-4.
  15. Lertkhachonsuk R, Tantbirojn P, Paiwattananupant K (2012b). PTEN and MDM2 expression in the prediction of postmolar gestational trophoblastic neoplasia. J Reprod Med, 57, 333-40.
  16. Lurain JR (2010). Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol, 203, 531-9.
  17. Merchant SH, Amin MB, Viswanatha DS, et al (2005). p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses. Hum Pathol, 36, 180-6.
  18. Mosher R, Goldstein DP, Berkowitz R, et al (1998). Complete hydatidiform mole. Comparison of clinicopathologic features, current and past. J Reprod Med, 43, 21-7.
  19. Ngan HY, Kohorn EI, Cole LA, et al (2012). Trophoblastic disease. Int J Gynaecol Obstet, 119, 130-6.
  20. Paradinas FJ, Browne P, Fisher RA, et al (1996). A clinical, histopathological and flow cytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathol, 28, 101-10.
  21. Pateras IS, Apostolopoulou K, Niforou K, et al (2009). p57KIP2: "Kip"ing the cell under control. Mol Cancer Res, 7, 1902-19.
  22. Petts G, Fisher RA, Short D, et al (2014). Histopathological and immunohistochemical features of early hydatidiform mole in relation to subsequent development of persistent gestational trophoblastic disease. J Reprod Med, 59, 213-20.
  23. Popiolek DA, Yee H, Mittal K, et al (2006). Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole. Hum Pathol, 37, 1426-34.
  24. Sasaki S, Sasaki Y, Kunimura T, et al (2015). Clinical Usefulness of Immunohistochemical Staining of p57 kip2 for the Differential Diagnosis of Complete Mole. Biomed Res Int, 2015, 905648.
  25. Sebire NJ, Fisher RA, Rees HC (2003a). Histopathological diagnosis of partial and complete hydatidiform mole in the first trimester of pregnancy. Pediatr Dev Pathol, 6, 69-77.
  26. Sebire NJ, Foskett M, Short D, et al (2007). Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG, 114, 760-2.
  27. Sebire NJ, Makrydimas G, Agnantis NJ, et al (2003b). Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res, 23, 1723-8.
  28. Seckl MJ, Sebire NJ, Berkowitz RS (2010). Gestational trophoblastic disease. Lancet, 376, 717-29.
  29. Seckl MJ, Sebire NJ, Fisher RA, et al (2013). Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24, 39-50.
  30. Wairachpanich V, Limpongsanurak S, Lertkhachonsuk R (2015). Epidemiology of hydatidiform moles in a tertiary hospital in Thailand over two decades: impact of the national health policy. Asian Pac J Cancer Prev, 16, 8321-5.
  31. Xu XY, Wang WQ, Zhang L, et al (2012). Clinical implications of p57 KIP2 expression in breast cancer. Asian Pac J Cancer Prev, 13, 5033-6.